Subcutaneous vs. orthotopic tumor models: A comparative assessment

Analysis of tumor heterogeneity in syngeneic models; CT26.WT colon carcinoma and 4T1-Luc2-1A4 breast carcinoma in female BALB/cAnNHsd mice

Digital spatial profiling of MC38 colon carcinoma following checkpoint inhibition

Graphical Summary: The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer

Molecular Tumor Board: 65-year-old male with recurrent hepatocellular carcinoma

In this molecular tumor board, our Medical Affairs Team presents a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.

Molecular Tumor Board: 71-year-old female with intrahepatic cholangiocarcinoma and IDH1 R132C mutation

In this molecular tumor board, our Oncology Medical Affairs Team presents a case of a 71-year-old female with intrahepatic cholangiocarcinoma whose tumor harbors an IDH1 R132C mutation. Watch as they discuss options for targeted therapy, side effects, and the biologic rationale.

Molecular Tumor Board: 44-year-old male with advanced NSCLC and ROS1 fusion

This Molecular Tumor Board, our Oncology Medical Affairs team reviews concurrent tissue- and plasma-based comprehensive NGS testing for the management of a young patient with advanced stage NSCLC. A growing number of guideline-recommended biomarkers are reviewed for frontline targeted therapy selection and prevalence of oncogenic driver alterations in NSCLC. The process of utilizing and optimizing cytology specimens for NGS analysis is also discussed.

2024 ASCO® Annual Meeting

Implementing liquid biopsy testing in a routine lab

Molecular Tumor Board: 65-year-old male with recurrent hepatocellular carcinoma

This molecular tumor board where we present a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.